Dowdy Jackson
Chief Executive Officer Jackson Consulting Group
Seminars
Thursday 6th November 2025
Workshop highlights include:
- Breaking down the desired characteristics for “clean” ADC targets and risk-benefit analysis for first-in-class therapeutics
- Exploring successes and challenges with emerging anti-tumor ADC targets
- Evaluating the opportunity of bispecific ADCs in target innovation
- Leveraging bioinformatics and omics technologies to screen and identify novel ADC targets
